[Therapy of infantile spasms (West syndrome) with sodium dipropylacetate]

Insights

Sodium Dipropylacetic acid (DPK) effectively reduced infantile spasms in 40% of idiopathic cases and 11% of secondary cases. Long-term follow-up showed persistent seizures in some patients, with mental retardation noted in both groups.

Area of Science:

  • Pediatric Neurology
  • Clinical Pharmacology

Context:

  • Infantile spasms syndrome (ISS) is a severe epilepsy syndrome in infants.
  • Treatment options for ISS include anticonvulsants and hormonal therapy.

Purpose:

  • To evaluate the efficacy and long-term outcomes of Sodium Dipropylacetic acid (DPK) in treating infantile spasms.
  • To compare treatment responses based on etiology (idiopathic vs. secondary ISS).

Summary:

  • 42 patients with infantile spasms were treated with DPK, divided into idiopathic and secondary groups.
  • DPK showed varying efficacy: 40% seizure-free in idiopathic, 11.1% in secondary. Long-term follow-up revealed persistent seizures in 18.18% (idiopathic) and 28.57% (secondary).
  • Mental retardation was observed in 36.36% of idiopathic and 57.14% of secondary cases.

Impact:

  • DPK demonstrates significant efficacy in managing infantile spasms, particularly in idiopathic cases.
  • The study highlights the importance of considering etiology for treatment strategies in infantile spasms.
  • Findings support the use of anticonvulsants as a first-line treatment for ISS, with hormonal therapy (ACTH) reserved for refractory cases.

Related Concept Videos

Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Tetanus01:29

Tetanus

Tetanus is a life-threatening neurological disorder characterized by persistent muscle contractions and spastic paralysis. It is caused by Clostridium tetani, a motile, Gram-positive, rod-shaped, obligate anaerobe. These bacteria produce terminal endospores, giving them a distinctive “lollipop” or “tennis-racket” appearance. They thrive in anaerobic environments, such as those found in deep puncture wounds.Once introduced into the body, the spores germinate into vegetative cells. These cells...